ea0092op-10-01 | Oral Session 10: Novel diagnostics in Thyroid cancer | ETA2023
Stegenga Merel
, Oudijk Lindsey
, Van Velsen Evert
, Medici Marco
, Peeters Robin
, Edward Visser W.
, van Kemenade Folkert
Introduction: Historically, treatment of follicular thyroid carcinoma (FTC) and oncocytic thyroid carcinoma (OTC) is based on thyroidectomy followed by radioiodine (RAI) therapy. Both tumor types have a good prognosis (10-year survival 80-94%), but this changes significantly once RAI-refractory disease occurs (median 3.5 years), which limits further treatment possibilities. The main risk factors for developing RAI-refractory disease in FTC and OTC are unknown. Our aim was to i...